Filing Flows › Artivion (AORT) › Recalls, complaints & regulation
Artivion (AORT): recalls and clinical trials
Artivion (AORT) beyond its filings: 0 recalls in the last 12 months (3 in five years, 0 Class I); 3 active clinical trials.
Latest recalls
- 2024-08-14 · FDA device · (1) CryoPatch SG Pulmonary Human Cardiac Hemi-Artery - Artery Patch, SGPH00 Cryopreserved Decellularized Cardiac Tissue Allograft Prepared with SynerGraft (SG)
- 2024-08-14 · FDA device · CryoValve SG Pulmonary Human Heart Valve, SGPV00, Cryopreserved Decellularized Heart Valve Allograft Prepared with SynerGraft (SG) Technology.
- 2024-04-24 · FDA device · CryoValve SG Cryopreserved Pulmonary Human Heart Valve
Artivion's latest quarter
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
Has Artivion had any recalls?
3 recalls on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Artivion have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.